# Two River

> Two River is a VC fund in New York backing Health Care and Biotechnology. See 14 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: New York, United States
- Total investments: 14
- Last investment: Sep 2024
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/two-river/about/
- Website: http://www.tworiver.com/

Two River is a VC fund in New York focused on Health Care and Biotechnology. We work with experienced teams to build outstanding companies that improve health outcomes and quality of life. At Two River we tailor our approach to the needs of each opportunity, partnering with management to create, finance or operate development-stage companies in the life sciences and healthcare sectors.Two River invests in companies withstrong intellectual property and proven leadership teams who have demonstrated prior success developing innovative technologies in the life sciences sector.Two River is uniquely positioned to understand and balance the needs of the finance and life science communities. Our experience building companies spans a range of industry sectors including oncology, cardiovascular disease, ophthalmology, neurological disorders and animal health. We consider each of our investments to be a partnership, often working closely with portfolio companies on product development, regulatory and corporate strategy as well as day-to-day business operations.

## Contacts

5 contacts available for Two River. Shizune tracks 3 team members at Two River. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/two-river?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 6 | 43% |
| Biotechnology | 6 | 43% |
| Therapeutics | 4 | 29% |
| Wellness | 3 | 21% |
| Medical | 2 | 14% |

15 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 8 | 57% |
| Series B | 2 | 14% |
| Funding Round | 2 | 14% |
| Series C | 1 | 7% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 8 | 57% |
| The Netherlands | 1 | 7% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Arie Belldegrun | Chairman & Partner | 5 | https://shizune.co/investors/profile/arie-belldegrun |
| David M. Tanen | Partner | 0 | https://shizune.co/investors/profile/david-m-tanen |
| Joshua Kazam | Co-Founder & Partner | 5 | https://shizune.co/investors/profile/joshua-a-kazam |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Candid Therapeutics | Candid Therapeutics is a biotechnology company that focuses on the treatment of a range of immunological conditions. | $370M | Series B | Sep 09, 2024 |  |
| Candid Therapeutics | Candid Therapeutics is a biotechnology company that focuses on the treatment of a range of immunological conditions. | $370M | Series A | Sep 09, 2024 |  |
| ByHeart | ByHeart operates as a fully integrated infant nutrition company. It is dedicated to translating leading nutrition science and breastmilk research into evolved foods and formulas to support babies’ health and parents’ peace of mind. Its products strive to be next to nature made from hand-picked ingredients using small-batch blending and sit at theforefront of immune, microbiome, cognitive, and digestive health.The company was founded in 2016 and is headquartered in New York. | $95M |  | May 13, 2024 |  |
| ByHeart | ByHeart operates as a fully integrated infant nutrition company. It is dedicated to translating leading nutrition science and breastmilk research into evolved foods and formulas to support babies’ health and parents’ peace of mind. Its products strive to be next to nature made from hand-picked ingredients using small-batch blending and sit at theforefront of immune, microbiome, cognitive, and digestive health.The company was founded in 2016 and is headquartered in New York. | $95M | Series C | May 13, 2024 |  |
| ByHeart | ByHeart operates as a fully integrated infant nutrition company. It is dedicated to translating leading nutrition science and breastmilk research into evolved foods and formulas to support babies’ health and parents’ peace of mind. Its products strive to be next to nature made from hand-picked ingredients using small-batch blending and sit at theforefront of immune, microbiome, cognitive, and digestive health.The company was founded in 2016 and is headquartered in New York. | $90M | Series B | Jul 26, 2021 |  |
| IconOVir Bio | IconOVir Bio is a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus therapy to improve the treatment of patients with cancer. | $77M | Series A | Jan 05, 2021 |  |
| Neogene Therapeutics | Neogene Therapeutics provides cancer patients with T cell therapies targeting mutated proteins called neo-antigens. The company is developing novel technologies to enable the engineering of ‘designer T cells’ with neo-antigen specificities that display an optimized ability to seek and destroy cancer cells.Neogene's platform allows for theisolation of neo-antigen specific TCR genes from tumor biopsies that are routinely obtained from cancer patients during treatment. The tumor-infiltrating lymphocytes (TIL) obtained by these tumor biopsies frequently express TCRs specific for mutated proteins found in cancer cells (neo-antigens). The company’s proprietary technology uses state-of-the-art DNA sequencing, DNA synthesis and genetic screening tools to identify such neo-antigen specific T cell receptor genes within tumor biopsies with high sensitivity, specificity and at scale. | $110M | Series A | Sep 14, 2020 |  |
| ByHeart | ByHeart operates as a fully integrated infant nutrition company. It is dedicated to translating leading nutrition science and breastmilk research into evolved foods and formulas to support babies’ health and parents’ peace of mind. Its products strive to be next to nature made from hand-picked ingredients using small-batch blending and sit at theforefront of immune, microbiome, cognitive, and digestive health.The company was founded in 2016 and is headquartered in New York. | $70M | Series A | Apr 15, 2020 |  |
| Amunix | Amunix is a biopharmaceutical company intended to discover, design, and develop novel biologics, protein, and peptide therapeutics. The company is focused on developing prodrugs to bring the promise of potent immune-activating biotherapeutics to patients with solid tumor cancers. By delivering breakthrough therapies that can safely harness theimmune system, it aims to conquer cancer and save lives. Its pipeline products are based on its proprietary XTEN half-life extension, XDC drug-conjugate delivery, and ProTIA pro-drug, bispecific T cell engager platform and have ongoing collaborations with biopharma corporations harnessing these delivery technologies over a wide range of therapeutic areas, delivering improved pharmaceutical technologies.Amunix was founded in 2006 and is headquartered in Mountain View, California. | $73M | Series A | Mar 04, 2020 |  |
| Thirty Madison | Thirty Madison is a virtual care company that provides treatment for chronic conditions. The company operates a portfolio of specialized brands that deliver personalized care and treatments. It partners with health plans and employers to provide its services as a covered benefit. | $15.3M | Series A | Oct 16, 2018 |  |

10 of 14 investments shown.

## Co-investors
- [Bellco Capital](https://shizune.co/investors/profile/bellco-capital) — VC Fund, 8 deals together
- [Polaris Partners](https://shizune.co/investors/profile/polaris-partners) — VC Fund, 8 deals together
- [D1 Capital Partners](https://shizune.co/investors/profile/d1-capital-partners) — VC Fund, 4 deals together
- [Greycroft](https://shizune.co/investors/profile/greycroft) — VC Fund, 4 deals together
- [OCV](https://shizune.co/investors/profile/ocv) — VC Fund, 4 deals together
- [Red Sea Ventures](https://shizune.co/investors/profile/red-sea-venture-partners) — VC Fund, 4 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Two River invest in?

Two River invests primarily in Health Care, Biotechnology and Therapeutics startups, most often at Series A and Series B stage. Most of the 14 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Two River?

Public channels for Two River include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Two River?

The team at Two River includes Arie Belldegrun (Chairman & Partner), David M. Tanen (Partner) and Joshua Kazam (Co-Founder & Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co